Efficacy and safety of fenfluramine in the treatment of Dravet syndrome - literature review
DOI:
https://doi.org/10.12775/JEHS.2022.12.01.008Keywords
fenfluramine, Dravet syndrome, epilepsy treatment, seizure frequency, pharmacokineticsAbstract
Dravet Syndrome is a severe, drug-resistant, and rare epileptiform disorder that is typically presented in the first year of life in an otherwise healthy child. It is characterized by prolonged seizures that are often resistant to current anti-epileptic drug regimens, which made them poorly controlled, and almost 50% of patients experience at least four tonic-clonic seizures per month. There are three new medicines: stiripentol, cannabidiol, and fenfluramine, with documented efficacy and safety as adjunctive therapies in pharmacoresistant Dravet syndrome treatment.
This study aimed to assess the efficacy and safety of fenfluramine in the treatment of Dravet syndrome. Our study material consisted of publications, which were found in PubMed, Google Scholar, and Embase databases. In order to find the proper publications, the search has been conducted with the use of a combination of keywords like: “fenfluramine”, “Dravet syndrome”, “epilepsy treatment”, “Dravet syndrome pediatric patients”. The first step was to find proper publications from the last 10 years. The second step was to carry out an overview of the found publications.
Results of mentioned studies proved that in Dravet syndrome, fenfluramine provided a significantly greater reduction in convulsive seizure frequency compared with placebo. No patient developed valvular heart disease or pulmonary arterial hypertension, the side effects that occurred during its use were mild and the drug was generally well-tolerated. The bioequivalence and tolerability of single oral doses of fenfluramine hydrochloride oral solution in the fed and fasted states support drug administration without regard to meals. Fenfluramine may represent a new important treatment option for Dravet syndrome.
References
Zhang L, Li W, Wang C. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis. Acta Neurol Scand. 2021 Apr;143(4):339-348. doi: 10.1111/ane.13387. Epub 2020 Dec 17. PMID: 33336426.
Simon K, Sheckley H, Anderson CL, Liu Z, Carney PR. A review of fenfluramine for the treatment of Dravet syndrome patients. Curr Res Pharmacol Drug Discov. 2021 Dec 16;3:100078. doi: 10.1016/j.crphar.2021.100078. PMID: 34988433; PMCID: PMC8695265.
Polster T. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav. 2019 Feb;91:99-102. doi: 10.1016/j.yebeh.2018.08.021. Epub 2018 Sep 28. PMID: 30269941.
Wheless JW, Fulton SP, Mudigoudar BD. Dravet Syndrome: A Review of Current Management. Pediatr Neurol. 2020 Jun;107:28-40. doi: 10.1016/j.pediatrneurol.2020.01.005. Epub 2020 Jan 31. PMID: 32165031.
Gogou M, Cross JH. Fenfluramine as antiseizure medication for epilepsy. Dev Med Child Neurol. 2021 Aug;63(8):899-907. doi: 10.1111/dmcn.14822. Epub 2021 Feb 9. PMID: 33565102.
Sullivan J, Simmons R. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies. Drugs Today (Barc). 2021 Jul;57(7):449-454. doi: 10.1358/dot.2021.57.7.3284619. PMID: 34268532.
Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015 Nov;8(6):328-38. doi: 10.1177/1756285615607726. PMID: 26600876; PMCID: PMC4643872.
Odi R, Invernizzi RW, Gallily T, Bialer M, Perucca E. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. Pharmacol Ther. 2021 Oct;226:107866. doi: 10.1016/j.pharmthera.2021.107866. Epub 2021 Apr 22. PMID: 33895186.
Balagura G, Cacciatore M, Grasso EA, Striano P, Verrotti A. Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs. 2020 Oct;34(10):1001-1007. doi: 10.1007/s40263-020-00755-z. PMID: 32875491.
Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020 Apr;105:106989. doi: 10.1016/j.yebeh.2020.106989. Epub 2020 Mar 10. PMID: 32169824.
Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394(10216):2243-2254. doi: 10.1016/S0140-6736(19)32500-0. Epub 2019 Dec 17. PMID: 31862249.
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. PMID: 31790543; PMCID: PMC6902175.
Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, Polster T, Galer B, Lock M, Agarwal A, Gammaitoni A, Morrison G, Farfel G. Fenfluramine HCl (Fintepla® ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study. Epilepsia. 2020 Nov;61(11):2396-2404. doi: 10.1111/epi.16722. Epub 2020 Oct 19. PMID: 33078386; PMCID: PMC7756901.
Specchio N, Pietrafusa N, Doccini V, Trivisano M, Darra F, Ragona F, Cossu A, Spolverato S, Battaglia D, Quintiliani M, Luigia Gambardella M, Rosati A, Mei D, Granata T, Dalla Bernardina B, Vigevano F, Guerrini R. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study. Epilepsia. 2020 Nov;61(11):2405-2414. doi: 10.1111/epi.16690. Epub 2020 Sep 18. PMID: 32945537.
Sullivan J, Perry MS, Wheless JW, Galer B, Gammaitoni A. Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice. Eur J Paediatr Neurol. 2021 Mar;31:10-14. doi: 10.1016/j.ejpn.2021.01.005. Epub 2021 Jan 22. PMID: 33540241.
Bishop KI, Isquith PK, Gioia GA, Gammaitoni AR, Farfel G, Galer BS, Nabbout R, Wirrell EC, Polster T, Sullivan J. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome. Epilepsy Behav. 2021 Aug;121(Pt A):108024. doi: 10.1016/j.yebeh.2021.108024. Epub 2021 May 20. PMID: 34023810.
Lai WW, Galer BS, Wong PC, Farfel G, Pringsheim M, Keane MG, Agarwal A. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020 Nov;61(11):2386-2395. doi: 10.1111/epi.16638. Epub 2020 Aug 18. PMID: 32809271; PMCID: PMC7754414.
Schoonjans AS, Marchau F, Paelinck BP, Lagae L, Gammaitoni A, Pringsheim M, Keane MG, Ceulemans B. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017 Oct;33(10):1773-1781. doi: 10.1080/03007995.2017.1355781. Epub 2017 Jul 31. PMID: 28704161.
Gammaitoni A, Smith S, Boyd B. The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study. Clin Ther. 2018 Aug;40(8):1338-1346. doi: 10.1016/j.clinthera.2018.05.013. Epub 2018 Jun 23. PMID: 29941151.
Boyd B, Smith S, Gammaitoni A, Galer BS, Farfel GM. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects . Int J Clin Pharmacol Ther. 2019 Jan;57(1):11-19. doi: 10.5414/CP203276. PMID: 30336805; PMCID: PMC6298132.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Martyna Stefaniak, Zofia Pietrzak, Piotr Dzikowski, Emilia Nowicka, Michał Obel, Halina Piecewicz-Szczęsna
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 563
Number of citations: 0